收藏切换
Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer
收藏切换
Yuting YAN, Jieyu SUN, Qian LI*
World Clinical Drug | 2024, 45(3) : 317 - 323
Less
收藏切换
World Clinical Drug | 2024, 45(3): 317-323
• Article •
Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer
Full
Yuting YAN, Jieyu SUN, Qian LI*
Affiliations
  • Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
Published: 2024-03-10 doi: 10.13683/j.wph.2024.03.013
Outline
收藏切换
Objective

To evaluate the safety, efficacy and economy of lorlatinib as the first-line treatment in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by rapid health technology assessment (rHTA), and to provide evidence for clinical decision makers.

Methods

Domestic and foreign databases and other major official HTA websites were used, and the related literatures about lorlatinib as first-line treatment for ALK mutation-positive NSCLC patients were included and comprehensively analyzed.

Results

A total of 9 systematic/meta-analyses and 4 economic studies were included. Efficacy results showed that objective response rate and progression-free survival of lorlatinib were significantly better than other ALK-tyrosine kinase inhibitors and chemicals, but overall survival was not significantly different. Safety results showed that the incidence of adverse events of lorlatinib≥3 was only lower than ceritinib, but controllable. Economic results did not show a significant cost-effectiveness advantage.

Conclusion

Lorlatinib has efficacy and safety advantages in the first-line treatment of ALK mutation-positive NSCLC patients, but its economic advantages need to be further studied. More safety, effectiveness and economic studies focusing on intuitive comparison and multi-subgroup are necessary.

lorlatinib  /  non-small cell lung cancer  /  rapid health technology assessment
闫雨婷, 孙洁雨, 李茜. 洛拉替尼一线治疗间变性淋巴瘤激酶突变阳性非小细胞肺癌患者的快速卫生技术评估. 世界临床药物, 2024 , 45 (3) : 317 -323 . DOI: 10.13683/j.wph.2024.03.013
Yuting YAN, Jieyu SUN, Qian LI. Rapid health technology assessment of lorlatinib in the first-line treatment of anaplastic lymphoma kinase mutation-positive non-small cell lung cancer[J]. World Clinical Drug, 2024 , 45 (3) : 317 -323 . DOI: 10.13683/j.wph.2024.03.013
Year 2024 volume 45 Issue 3
12
1
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.03.013
  • Receive Date:2023-08-04
  • Online Date:2026-11-18
  • Published:2024-03-10
Article Data
Affiliations
History
  • Received:2023-08-04
Affiliations
    Department of Pharmacy, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.03.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT